AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00876811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
Study NCT00876811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individually quick frozen red raspberries
Description: Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
Study NCT02937662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
Study NCT02937662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 100mg/㎡/d on days 1-7.
Study NCT02937662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
Study NCT02937662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician-Directed Regimens without Cyclophosphamide
Description: Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
Study NCT03039413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Given IV
Study NCT03039413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Cu-64-TP3805 Positron Emission Tomography scan
Study NCT00323271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Description: CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
Study NCT00323271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional
Description: Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
Study NCT01577966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA.
Study NCT04078087 — intervention group
Intervention type: DRUG
Intervention: Non obese
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Study NCT04078087 — intervention group
Intervention type: DRUG
Intervention: Obese.
Description: After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
Study NCT04715737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of vasopressin (20IU) intranasally
Study NCT04715737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of oxytocin (24IU) intranasally
Study NCT04715737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo intranasally
Study NCT01329705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study NCT01329705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized
Study NCT02080065 — intervention group
Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Study NCT03674827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06936308
Description: PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
Study NCT02445222 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Previously treated CAR-T patients
Description: Lentiviral-based CAR-T cell therapy
Study NCT01173588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yogurt added with bifidobacteria and soluble fiber (YBF)
Description: Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
Study NCT01173588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: yogurt added with bifidobacteria and soluble fiber (YBF)
Description: Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
Study NCT05504369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic tape
Description: Tape with magnetic nanoparticles applied to the skin
Study NCT05504369 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo tape
Description: Tape without nano particles applied to the skin
Study NCT03039413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Cu-64-TP3805 Computed Tomography scan
Study NCT02520934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: combine miglustat and ERT to see if neurologic manifestations can be improved
Study NCT02520934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERT
Description: enzyme replacement therapy
Study NCT02858076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-mg Intravitreous Aflibercept Injection
Description: Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
Study NCT02858076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prompt Vitrectomy Plus Panretinal Photocoagulation
Description: Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
Study NCT02460133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paritaprevir
Study NCT02460133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Study NCT02460133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasabuvir
Study NCT02460133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir
Study NCT02460133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
Study NCT00877214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
Study NCT00877214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab / observation
Description: Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
Study NCT00929864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
Study NCT00929864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Study NCT02962869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
Study NCT02962869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT03874533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-adjustment tests
Description: For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant
Study NCT03528967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe
Study NCT03528967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg Oral Tablet, Enteric Coated
Study NCT03528967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 100 mg Oral Tablet, Enteric Coated
Study NCT00388115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Standard of care lumpectomy or mastectomy following RFA
Study NCT00388115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Standard of care lumpectomy or mastectomy following RFA
Study NCT02752620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Study NCT02752620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Study NCT00388115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
Study NCT02515461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy shockwave therapy
Description: Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG.
Study NCT01305265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cuff manometer
Description: endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
Study NCT02865642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin Uptake Inhibitors
Study NCT02865642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02029313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT02029313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT02029313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Study NCT02029313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Study NCT00647426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib + Docetaxel/Carboplatin
Description: 400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
Study NCT01485588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 60µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Study NCT01485588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 150µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Study NCT01485588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hI-con1™ 300µl
Description: Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
Study NCT01909388 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-TRUS fusion guided real time HDR
Study NCT01350531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills training
Description: This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
Study NCT01350531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
Study NCT01908998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sandal
Description: Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
Study NCT03220893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT
Study NCT03220893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintimammography
Description: Undergo MBI
Study NCT03216174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NESS-EFTR
Description: NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
Study NCT01308580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous
Study NCT02549274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-rehabilitation + physiotherapy
Description: 2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
Study NCT02549274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: 14 physiotherapy sessions (2 by week)
Study NCT02885259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: human immunoglobulin and one vial of recombinant human hyaluronidase
Study NCT01227954 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Description: 30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
Study NCT01885507 — intervention group
Intervention type: OTHER
Intervention: Pass recommendations on ventilation factors and extubation
Description: * the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough
Study NCT00563524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ILV-094
Description: SC and IV administration on days 1, 14, 28, and 42
Study NCT01728363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
Study NCT04440007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib
Description: Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
Study NCT04440007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator
Study NCT04440007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator
Study NCT03672396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
Study NCT04840628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance of the respiratory system
Description: increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
Study NCT04033627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro T cells depletion using CliniMCAS system
Description: Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
Study NCT02386722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartinhaler/POEMS with audio reminders and additional support calls
Description: Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
Study NCT01208168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB001
Description: nail lacquer, once daily, 52 weeks
Study NCT01208168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle alone
Description: nail lacquer, once daily, 52 weeks
Study NCT02040207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection
Study NCT01424618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
Study NCT01424618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.